Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is doing the opposite for its Enspryng study in the competitive autoimmune disorder of generalized myasthenia gravis (gMG).

Enspryng delivered a statistically significant benefit in improving symptoms and daily life metrics when used on top of standard-of-care therapy in gMG patients who are anti-AChR-seropositive, which represents about 80% of the disease population. The phase 3 LUMINESCE trial has met its primary endpoint as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at 24 weeks.

However, in announcing the positive readout, Roche’s Chugai said the degree of clinical benefit observed “did not reach our expectations.”

Drug developers often try to spot tidbits of positive information from a failed clinical trial. But Roche is doing the opposite for its Enspryng study in the competitive autoimmune disorder of generalized myasthenia gravis (gMG).

Enspryng delivered a statistically significant benefit in improving symptoms and daily life metrics when used on top of standard-of-care therapy in gMG patients who are anti-AChR-seropositive, which represents about 80% of the disease population. The phase 3 LUMINESCE trial has met its primary endpoint as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at 24 weeks.

However, in announcing the positive readout, Roche’s Chugai said the degree of clinical benefit observed “did not reach our expectations.”